journal article·2019-12-04Open access

Astragaloside-IV protects H9C2(2-1) cardiomyocytes from high glucose-induced injury via miR-34a-mediated autophagy pathway

Yaobin Zhu, Xin Qian, Jingjing Li, Xing Lin, Jiewei Luo, Jianbin Huang, Zhao Jin

Abstract

Diabetic cardiomyopathy (DCM) is an important cardiac disorder in patients with diabetes. High glucose (HG) levels lead to inflammation of cardiomyocytes, oxidative stress, and long-term activation of autophagy, resulting in myocardial fibrosis and remodelling. Astragaloside-IV (AS-IV) has a wide range of pharmacological effects. This study aimed to investigate the effects of AS-IV on injury induced by HG in rat cardiomyocytes (H9C2(2-1)) and the involvement of the miR-34a-mediated autophagy pathway. An AS-IV concentration of 100 μM was selected based on H9C2(2-1) cell viability using the cell counting kit-8 (CCK-8). We found that 33 mM HG induced a morphologic change in cells and caused excessive oxidative stress, whereas AS-IV inhibited lipid peroxidation and increased superoxide dismutase activity. In terms of mRNA expression, HG increased miR-34a and inhibited Bcl2 and Sirt1, whereas AS-IV and miR-34a-inhibitor reversed the above effects. Further, LC3-GFP adenovirus infection and western blotting showed that HG increased autophagy, which was reversed synergistically by AS-IV and miR-34a-inhibitor. Bcl2 and pAKT/AKT protein expressions in the HG group was significantly lower than that in controls, but AS-IV and miR-34a-inhibitor antagonized the process. Thus, AS-IV inhibits HG-induced oxidative stress and autophagy and protects cardiomyocytes from injury via the miR-34a/Bcl2/(LC3II/LC3I) and pAKT/Bcl2/(LC3II/LC3I) pathways.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Autophagy in Disease and Therapy · Electrospun Nanofibers in Biomedical Applications · Cardiovascular Function and Risk Factors

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Traditional Chinese Medicine, The First Affiliated Hospital, Fujian Medical University

Shengli Clinical Medical College of Fujian Medical University

Department of Traditional Chinese Medicine, Fujian Provincial Hospital

Funding

National Natural Science Foundation of China · Fujian Provincial health and family planning Youth research programme

References (46)

Show source-provided references
1. 10.1111/fcp.1223210.1111/fcp.12232 ↗
2. 10.1016/j.biopha.2019.10902810.1016/j.biopha.2019.109028 ↗
3. 10.1016/S1875-5364(15)60016-410.1016/S1875-5364(15)60016-4 ↗
4. 10.3389/fphys.2018.0079510.3389/fphys.2018.00795 ↗
5. 10.1186/s12933-017-0638-z10.1186/s12933-017-0638-z ↗
6. 10.3390/ijms1712213610.3390/ijms17122136 ↗
7. 10.1161/CIRCULATIONAHA.113.00386310.1161/CIRCULATIONAHA.113.003863 ↗
8. 10.3390/cells708010410.3390/cells7080104 ↗
9. 10.1007/978-981-10-4304-8_1510.1007/978-981-10-4304-8_15 ↗
10. 10.1007/s12020-018-1688-z10.1007/s12020-018-1688-z ↗
11. de la Ballina LR, Munson MJ, Simonsen A. Lipids and lipid-binding proteins in selective autophagy. J Mol Biol. 2019;pii:S0022-2836(19):30352–30353.
12. 10.1016/j.yjmcc.2011.03.00210.1016/j.yjmcc.2011.03.002 ↗
13. 10.1016/j.cellsig.2019.06.00410.1016/j.cellsig.2019.06.004 ↗
14. 10.1007/s00246-010-9855-x10.1007/s00246-010-9855-x ↗
15. 10.1089/dna.2014.275510.1089/dna.2014.2755 ↗
16. 10.1016/j.exger.2019.11063710.1016/j.exger.2019.110637 ↗
17. Brindley E, Hill TDM, Henshall DC. MicroRNAs as biomarkers and treatment targets in status epilepticus. Epilepsy Behav. 2019;3:pii: S1525-5050(19)30353-1.
18. Subramaniam S, Jeet V, Clements JA, et al. Emergence of microRNAs as key players in cancer cell metabolism. Clin Chem. 2019;17:pii: clinchem.2018.299651.
19. 10.1016/S0960-9822(02)00809-610.1016/S0960-9822(02)00809-6 ↗
20. 10.1016/j.virusres.2018.11.00110.1016/j.virusres.2018.11.001 ↗
21. 10.3389/fcvm.2017.0006210.3389/fcvm.2017.00062 ↗
22. 10.1161/CIRCRESAHA.117.30596210.1161/CIRCRESAHA.117.305962 ↗
23. 10.1007/s00592-010-0226-010.1007/s00592-010-0226-0 ↗
24. 10.1038/nature1191910.1038/nature11919 ↗
25. 10.18632/oncotarget.1146810.18632/oncotarget.11468 ↗
26. 10.1128/MCB.01453-0610.1128/MCB.01453-06 ↗
27. 10.4061/2011/59509210.4061/2011/595092 ↗
28. 10.1016/j.cellsig.2012.04.00910.1016/j.cellsig.2012.04.009 ↗
29. 10.1016/j.cell.2006.03.00910.1016/j.cell.2006.03.009 ↗
30. 10.1242/jcs.21430410.1242/jcs.214304 ↗
31. 10.1080/15548627.2015.110035610.1080/15548627.2015.1100356 ↗
32. 10.1007/s10238-012-0186-510.1007/s10238-012-0186-5 ↗
33. 10.1007/s11357-011-9324-310.1007/s11357-011-9324-3 ↗
34. 10.1038/sj.bjc.660590410.1038/sj.bjc.6605904 ↗
35. 10.1038/nm.332210.1038/nm.3322 ↗
36. 10.1038/ncb275710.1038/ncb2757 ↗
37. 10.1089/ars.2015.632210.1089/ars.2015.6322 ↗
38. 10.1016/j.biopha.2017.03.05610.1016/j.biopha.2017.03.056 ↗
39. 10.3389/fendo.2019.0018710.3389/fendo.2019.00187 ↗
40. 10.1042/CS2011056310.1042/CS20110563 ↗
41. 10.1080/15548627.2018.151150410.1080/15548627.2018.1511504 ↗
42. 10.1186/s12986-017-0200-810.1186/s12986-017-0200-8 ↗
43. 10.1155/2012/93573810.1155/2012/935738 ↗
44. 10.1177/030006051877871110.1177/0300060518778711 ↗
45. He KQ, Li WZ, Chai XQ, et al. AS-IV prevents kidney injury caused by iatrogenic hyperinsulinemia in a streptozotocin-induced diabetic rat model. Int J Mol Med. 2018;41(2):1078–1088.
46. 10.1248/cpb.c13-0055610.1248/cpb.c13-00556 ↗